The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Substudy-01 of the VELOCITY-HNSCC platform trial.
 
Riddhi Patel
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Kevin Harrington
Honoraria - Abbvie (Inst); ALX Oncology (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Flamingo Pharma (Inst); GlaxoSmithKline (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); PDS Biotechnology (Inst); PsiVac Ltd (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; Arcus Ventures; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
Lisa Licitra
Honoraria - ALTIS Omnia Pharma Service Srl; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; Bicara Therapeutics; Boehringer Ingelheim; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Medscape LLC; Merck Healtcare KGaA; Merck Serono; MSD; MSD; Purple Biotech; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Amaury Daste
Consulting or Advisory Role - BMS; Merck; Merus; MSD
Travel, Accommodations, Expenses - BMS; Merck
 
Irene Brana
Consulting or Advisory Role - AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim Spain; Cancer Expert Now; Gilead Sciences; Merck Sharp & Dohme; Merus
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD
Research Funding - AOP Health (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Hookipa Pharma (Inst); IDEAYA Biosciences (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tango Therapeutics (Inst); Tolremo (Inst); VCN Biosciences (Inst)
 
Muh-Hwa Yang
No Relationships to Disclose
 
Jin You
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Kun Xu
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Manish Monga
Employment - arcus biosciences; Bristol-Myers Squibb/Celgene
Stock and Other Ownership Interests - Arcus Biosciences; Bristol-Myers Squibb/Celgene
 
Ye Guo
Honoraria - BeiGene; Merck Serono; MSD; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD